Selected for the FY2025 “Advanced Service Creation Support Program Utilizing Digital Technology”
ProteoBridge Inc. (Head Office: Koto-ku, Tokyo; President & CEO: Ryo Kumagai) is pleased to announce that our business plan has been selected for the FY2025 “Advanced Service Creation Support Program Utilizing Digital Technology,” implemented by the Tokyo Metropolitan Small and Medium Enterprise Support Center.
The selected project is titled:
“Creation of a Service Enabling Complication Risk Assessment for connective tissue diseases (Scleroderma / Myositis) Using Technologies for Autoantibody Big-Data Acquisition and Analysis.”
In this project, we aim to evolve our A-Cube® research testing system—previously used primarily in research settings—into a diagnostic tool that clinic physicians can utilize in everyday medical practice. In scleroderma and myositis, one of the major challenges is that patients often do not reach appropriate specialists in time, resulting in progression of severe complications such as interstitial lung disease.
To address this issue, we will develop a system that enables physicians, including those at community hospitals, to identify complication risks at an early stage by building a risk assessment model based on autoantibody big data. This will support timely referrals to appropriate specialists and informed treatment decisions. Through this initiative, we aim to reduce the number of patients who experience severe disease progression or delayed diagnosis, and to contribute to the realization of preventive medicine in the field of connective tissue diseases.
■ Project Overview
Project Title: Creation of a Service Enabling Complication Risk Assessment for Connective tissue diseases (Scleroderma / Myositis) Using Technologies for Autoantibody Big-Data Acquisition and Analysis
Selected Program: FY2025 “Advanced Service Creation Support Program Utilizing Digital Technology”
Implementing Agency: Tokyo Metropolitan Small and Medium Enterprise Support Center
■ Objectives and Future Outlook
There are many patients in Japan suffering from scleroderma and myositis, and there is a strong need to establish a healthcare system that incorporates complication risk assessment from an early stage. This project aims to realize a framework that links patients to appropriate testing and preventive treatment by utilizing autoantibody big-data–based complication risk evaluation technologies.
By identifying complication risks ahead of time and enabling timely therapeutic intervention, the project is expected to prevent disease progression and facilitate effective use of limited specialists and healthcare resources. This not only benefits patients themselves but also contributes to improving the quality of life of the families who support their daily lives.
Furthermore, suppressing severe complications through early diagnosis and early treatment is expected to help reduce future healthcare expenditures. Through this project, we aim to establish a preventive healthcare model in the field of collagen diseases and contribute to the realization of a sustainable medical system.
【About ProteoBridge Inc.】
ProteoBridge Inc. is a biotechnology company dedicated to early disease detection and the realization of personalized medicine through biomarker research and analysis focused on autoantibodies.
Through collaborative development with research institutions and pharmaceutical companies, we strive to create innovative research testing and analytical technologies in the field of autoimmune diseases.
Address: 2-4-7 Aomi, Koto-ku, Tokyo
CEO: Ryo Kumagai
Founded: January 5, 2018
Website: https://proteo-bridge.co.jp/en/